Cadila Healthcare's subsidiary Zydus Cadila has received tentative approval from the USFDA to market Fingolimod Capsules in the strength of 0.25 mg (US RLD: Gilenya Capsules).
Earlier, in October 2020, the group was granted approval to market Fingolimod Capsules in the strength of .5mg. Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
At around 2:15 PM, Cadila Healthcare was trading at Rs619.65 apiece down by Rs4.7 or 0.75% on Sensex.